Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

Canadian Retinal Trials Group120 enrolled

Overview

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

120

Conditions

Age-Related Macular Degeneration

Interventions

Triamcinolone AcetonideDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Individuals with predominantly classic, subfoveal CNV secondary to AMD. * No previous PDT Treatment in study eye. Exclusion Criteria: * CNV from conditions, other than AMD. * Other disease that could be responsible for decreased vision.

Locations (1)

Eye Care Centre

Vancouver, British Columbia, Canada

Outcomes

Primary Outcomes

Changes in visual acuity from baseline.

Secondary Outcomes

Change in lesion characteristics from baseline.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.